Strides Pharma Science has allotted 10,000 equity shares under ESOP on 29 April 2024. Consequent to above, the paid-up share capital of the Company has increased from Rs. 91,89,97,140/- consisting of ,18,99,714 equity shares of Rs. 10/- each to Rs. 91,90,97,140/- consisting of 9,19,09,714 equity shares of Rs. 10/- each. Powered by Capital Market - Live News

Strides Pharma Science today announced that its step‐ down wholly owned subsidiary, Strides Pharma Global, Singapore, has received approval for Fluoxetine Tabs 10 mg and 20 mg, from the United States Food & Drug Administration (USFDA).   The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac�   Tablets of Eli Lilly.   Fluoxetine tablets has a market size of ~US$ 23.9 Mn as per IMS. This approval further strengthens the Company`s presence in the Fluoxetine portfolio, complementing the existing approval of Fluoxetine  capsules, which has a marketsize of US$106 Mn. The Fluoxetine tablets will be manufactured at the company`s facility in Puducherry. The company has 260 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with USFDA, of which 245 ANDAs have been approved. The company has set a target to launch ~ 60 new products over three years in the US.Powered by Capital Market - Live News

Strides Pharma Science announced that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Formulations Facility of Strides Alathur, a wholly owned subsidiary of the Company, at Alathur, Chennai during the week of 01 April 2024 to 05 April 2024. The inspection closed with two observations. Powered by Capital Market - Live News

Strides Pharma Science (Strides) today announced that its step�]down wholly owned subsidiary, Strides Pharma Global, Singapore, has received approval for Gabapentin Tablets USP, 600 mg and 800 mg, from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty LLC. Gabapentin tablets has a market size of ~US$140Mn as per IMS. This approval further strengthens the Company`s presence in the Gabapentin portfolio, complementing the existing approval of Gabapentin capsules, which has a market size of US$208Mn. The Gabapentin tablets will be manufactured at the company�fs facility in Puducherry.The company has 260 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with USFDA, of which 235+ ANDAs have been approved. The company has set a target tolaunch ~ 60 new products over three years in the US. Powered by Capital Market - Live News

Net profit of Strides Pharma Science reported to Rs 49.67 crore in the quarter ended December 2023 as against net loss of Rs 80.03 crore during the previous quarter ended December 2022. Sales rose 19.98% to Rs 1037.67 crore in the quarter ended December 2023 as against Rs 864.85 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales1037.67864.85 20 OPM %13.67-3.13 - PBDT71.31-59.36 LP PBT20.08-119.58 LP NP49.67-80.03 LP Powered by Capital Market - Live News